MNA
PTCT icon

Manning & Napier Advisors’s PTC Therapeutics PTCT Stock Holding History

Manning & Napier Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Buy
31
+17
+121% +$1.23K ﹤0.01% 701
2026
Q1 		$919 Sell
14
-111
-89% -$7.86K ﹤0.01% 578
2025
Q4 		$9.52K Buy
+125
New +$9.08K ﹤0.01% 400

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Manning & Napier Advisors's PTCT Position: Q2 2026 in Review

Manning & Napier Advisors increased its PTC Therapeutics (PTCT) stake by 121% in Q2 2026, buying an estimated $1.23K and bringing the position to 31 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Manning & Napier Advisors first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.52K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Manning & Napier Advisors held 31 shares of PTC Therapeutics worth $2.53K as of Q2 2026.
  • Manning & Napier Advisors bought 17 PTC Therapeutics shares in Q2 2026, an estimated $1.23K.
  • PTC Therapeutics made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #701 holding.
  • Manning & Napier Advisors first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Manning & Napier Advisors's PTC Therapeutics position peaked at $9.52K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.